Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – Clinical Infectious Diseases Related: Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
The post Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”. appeared first on Links Medicus.
[Preprint] 3rd AstraZeneca shot gives strong immunity.
Study: 3rd AstraZeneca shot gives strong immunity – Reuters Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet
The post [Preprint] 3rd AstraZeneca shot gives strong immunity. appeared first on Links Medicus.
SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical Related: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”. Commentary on Twitter (thread – click for more) Just published @natureA […]
The post SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting. appeared first on Links Medicus.
Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.
Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre
The post Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine. appeared first on Links Medicus.
Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases Invited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases Commentary on Twitter NEW—A phase 1/2 clinical trial […]
The post Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. appeared first on Links Medicus.
Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis.
Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis – JAMA Network Open Commentary: Did Covid-19 take your taste and smell? Here’s when they may return – CNN AND Lost Sense of Smell Returns for Almost All COVID Survivors – HealthDay
The post Study finds 96.1% of patients objectively recovered from anosmia 1 year after COVID-19 diagnosis. appeared first on Links Medicus.
IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in
Co-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America Related: Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.
The post IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in <10% of hospitalized COVID-19 patients)”. appeared first on Links Medicus.
Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.
Is one vaccine dose enough if you’ve had COVID? What the science says – Nature Related: Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection. Commentary on Twitter One vaccine dose for prior covid: @ElieDolgin reviews the recent data @Nature https://t.co/amJ4RcGtuWVaccination cards/proof should be modified […]
The post Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says. appeared first on Links Medicus.
Delta “Plus”: Scientists say too early to tell risk of Covid-19 variant.
Delta plus India: Scientists say too early to tell risk of Covid-19 variant – BBC See also: There are at least 200 known cases of the Delta Plus coronavirus variant worldwide. Here’s what we know – CNN AND
The post Delta “Plus”: Scientists say too early to tell risk of Covid-19 variant. appeared first on Links Medicus.
WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads.
WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads – CNBC Commentary on Twitter (thread – click for more) ⚠️WEAR MASK EVEN IF VACCINATED—Top @WHO leader urges masks against #DeltaVariant even if 2-dose vaxxed. "Vaccine alone won't stop community transmission. People need to use masks consistently, be in […]
The post WHO urges fully vaccinated people to continue to wear masks as delta Covid variant spreads. appeared first on Links Medicus.